Antisense-based cancer therapeutics: are we there yet?
Antisense-based cancer therapeutics: are we there yet?
复制标题
DOI：
10.1517/14728214.11.2.337
复制
发表时间：
2006-05-01
影响因子：
3.4
通讯作者：
Zhang, Ruiwen
中科院分区：
文献类型：
--
作者：
Rayburn, Elizabeth Rose;Wang, Hui;Zhang, Ruiwen
尽管近年来已经取得了重大进展，但仍然迫切需要用于人类癌症的新型、更有效且毒性更小的治疗剂。在许多新的分子疗法正在探索的癌症治疗，反义寡核苷酸是一个有前途的核酸为基础的方法，许多反义药物正在评估的临床前研究和临床试验中的几个抗癌反义药物。尽管反义寡核苷酸在肿瘤治疗中的应用还存在一些问题，但随着反义寡核苷酸在化学修饰、靶点选择和药物传递系统等方面的研究进展，反义寡核苷酸已成为肿瘤治疗的一种新方法。
Despite significant advances that have been made in recent years, there is still an urgent need for novel, more effective and less toxic therapeutics for human cancer. Among many new molecular therapeutics being explored for cancer therapy, antisense oligonucleotides are a promising nucleic acid-based approach, with numerous antisense agents being evaluated in preclinical studies and several anticancer antisense drugs in clinical trials. Although there are still a few problems facing the development of antisense strategies for cancer therapy, with progress made in chemical modifications, target selection and drug delivery systems, antisense oligonucleotides are emerging as a novel approach to cancer therapy used alone or in combination with conventional treatments such as chemotherapy and radiation therapy.